



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Jianxin Yang

Serial No.: 10/817,418

Filed: April 5, 2004

)
)
)
)
)
)

Group Art No. 1614

Examiner: TBA

Docket No: 006539.00109

For: Gene amplification and overexpression in cancer

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:


Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicant submits herewith Form PTO/SB/08, identifying information for consideration by the Examiner. A copy of the items of information is enclosed.

Applicant does not waive any rights to take appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the present application.

Consideration of the cited information and making the same of record in the prosecution of the above-noted application are respectfully requested. Should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.



By:


Joseph M. Skerpon

Registration No: 29,864

Dated: November 11, 2005

1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 824-3000

PTO/SB/08a (08-03)



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/817,418
Filing Date	April 5, 2004
First Named Inventor	Jianxin YANG
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	006539.00109

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	"NICHOLLS, et al., "Thermogenic Mechanisms in Brown Fat", 1984, 1-64, Vol. 64, No. 1, The American Physiological Society.	
	2	YOSHIMOTO, et al., "Increased Expression of the c-myc Gene Without Gene Amplification in Human Lung Cancer and Colon Cancer Cell Lines", Jpn. J. Cancer Res., June 1986, 540-545, Vol. 77.	
	3	MUKAI, et al., "A Novel Protein Kinase with Leucine Zipper-Like Sequences: Its Catalytic Domain is Highly Homologous to that of Protein Kinase C", Biochemical and Biophysical Research Communications, March 15, 1994, 897-904, Vol. 199, No. 2.	
	4	"PALMER, et al., "Identification of Multiple, Novel, Protein Kinase C-Related Gene Products", FEBS Letters, 17 October 1994, 5-8, Vol. 356.	
	5	PALMER, et al., "Cloning and Expression Patterns of Two Members of a Novel Protein-Kinase-C-Related Kinase Family", Eur. J. Biochem., 1995, 344-351, Vol. 227.	
	6	KITAGAWA, et al., "Purification and Characterization of a Fatty Acid-Activated Protein Kinase (PKN) from rat testis", Biochem. J., 1995, 657-664, Vol. 310.	
	7	"MAYO, et al., "Heparin Binding to Platelet Factor-4", Biochem. J., 1995, 357-365, Vol. 312.	
	8	SANFILIPPO, et al., "Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion", J. Med. Chem., 1995, 1057-1059, Vol. 38.	
	9	BOSS, et al., "Uncoupling protein-3: A New Member of the Mitochondrial Carrier Family with Tissue-Specific Expression", FEBS Letters, 1997, 39-42, Vol. 408.	
	10	BOUCHARD, et al., "Linkage Between Markers in the Vicinity of the Uncoupling Protein 2 Gene and Resting Metabolic Rate in Humans", Human Molecular Genetics, 1997, 1887-1889, Vol. 6, No.11.	
	11	MILLET, et al., "Increased Uncoupling Protein-2 and -3 mRNA Expression during Fasting in Obese and Lean Humans", J. Clin. Invest., Dec. 1997, 2665-2670, Vol. 100, Number 11.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/817,418		
		Filing Date	April 5, 2004		
		First Named Inventor	Jianxin YANG		
		Art Unit	1614		
		Examiner Name	TBA		
Sheet	3	of	4	Attorney Docket Number	006539.00109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	FLEURY, et al., "Uncoupling Protein-2: A Novel Gene Linked to Obesity and Hyperinsulinemia", Nature Genetics, 1997, 269-272, Vol. 15.	
	13	KNUUTILA, et al., "DNA Copy Number Amplifications in Human Neoplasms", American Journal of Pathology, May 1998, 1107-1123, Vol. 152, No. 5.	
	14	. ARGYROPOULOS, et al., "Effects of Mutations in the Human Uncoupling Protein 3 Gene on the Respiratory Quotient and Fat Oxidation in Severe Obesity and Type 2 Diabetes", J. Clin. Invest., 1998, 1345-1351, Vol. 102.	
	15	BARTSCH, et al., "The Protein Kinase N (PKN) Gene PRKCL1/Prkcl1 Maps to Human Chromosome 19p12-p13.1 and Mouse Chromosome 8 with Close Linkage to the Myodystrophy (myd) Mutation", Genomics, 1998, 129-132, Vol. 49, Academic Press.	
	16	BOSS, et al., "Genomic Structure of Uncoupling Protein-3 (UCP3) and Its Assignment to Chromosome 11q13", Genomics, 1998, 425-426, Vol. 47.	
	17	GURA, "Uncoupling Proteins Provide New Clue to Obesity's Causes", Science, 29 May 1998, 1369-1370, Vol. 280, Issue 5368.	
	18	KNUUTILA, et al., "Comparative Genomic Hybridization Study on Pooled DNAs from Tumors of One Clinical-Pathological Entity", Cancer Genet Cytogenet, 1998, 25-30, Vol. 100.	
	19	SCARPACE, et al., "UCP2, UCP3 and Leptin Gene Expression: Modulation by Food Restriction and Leptin", Journal of Endocrinology, 1998, 349-357, Vol. 159.	
	20	HASHIMOTO, et al., "Localization of PKN mRNA in the Rat Brain", Molecular Brain Research, 1998, 143-153, Vol. 59.	
	21	SURWIT, et al., "Diet-Induced Changes in Uncoupling Proteins in Obesity-Prone and Obesity-Resistant Strains of Mice", Proc. Natl. Acad., March 1998, 4061-4065, Vol. 95.	
	22	LENGAUER, et al., "Genetic Instabilities in Human Cancers", NATURE, 17 Dec. 1998, 643-649, Vol. 396.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number

10/817,418

Filing Date

April 5, 2004

First Named Inventor

Jianxin YANG

Art Unit

1614

Examiner Name

TBA

Attorney Docket Number

006539.00109

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	NAEGER, et al., "Identification of a STAT4 Binding Site in the Interleukin-12 Receptor Required for Signaling", The Journal Of Biological Chemistry, 1999, 1875-1878, Vol. 274, No. 4.	
	24	OISHI, et al., "Identification and Characterization of PKN beta, a Novel Isoform of Protein Kinase PKN: Expression and Arachidonic Acid Dependency Are Different from Those of PKN alpha", Biochemical and Biophysical Research Communications, 1999, 808-814, Vol. 261.	
	25	GONG, et al., "Lack of Obesity and Normal Response to Fasting and Thyroid Hormone in Mice Lacking Uncoupling Protein-3", The Journal of Biological Chemistry, Dec. 22, 1999, 16251-16257.	
	26	BROWN, et al., "Endogenous Mutations in Human Uncoupling Protein 3 alter its Functional Properties", FEBS, 1999, 189-193, Vol. 464.	
	27	LU, et al., "The Drosophila Pkn protein Kinase is a Rho/Rac Effector Target Required for Dorsal Closure During Embryogenesis", GENES & DEVELOPMENT, 1999, 1168-1180, Vol. 13.	
	28	VIDAL-PUIG, et al., "Energy Metabolism in Uncoupling Protein 3 Gene Knockout Mice", Journal of Biological Chemistry, 2000, 16258-16266, Vol. 275, No. 21.	
	29	CLAPHAM, et al., "Mice Overexpressing Human Uncoupling Protein-3 in Skeletal Muscle are Hyperphagic and Lean", Nature, 27 July 2000, 415-418, Vol. 406.	
	30	BRUMMELKAMP, et al., "A system for stable expression of short interfering RNAs in mammalian cells", Science, 2002 Apr. 19, 550-553, Vol. 296 (5567).	
	31	METZGER, et al. "A Novel Inducible transactivation domain in the androgen receptor: Implications for PRK in prostate cancer", The EMBO Journal, 2003, 270-280, Vol. 22 No. 2	
	32	SILVERTOWN, et al., "Relaxin-Like Peptides in Cancer", Int. J. Cancer, 2003, 513-519, Vol. 107, Wiley-Liss, Inc.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.